Association between parity and pregnancy-associated tumor features in high-grade serous ovarian cancer

被引:1
|
作者
Skoeld, Camilla [1 ]
Corvigno, Sara [2 ]
Dahlstrand, Hanna [2 ]
Enblad, Gunilla [1 ]
Mezheyeuski, Artur [3 ]
Sundstroem-Poromaa, Inger [4 ]
Stalberg, Karin [4 ]
Tolf, Anna [1 ]
Glimelius, Ingrid [1 ,5 ]
Koliadi, Anthoula [1 ]
机构
[1] Uppsala Univ, Dept Immunol Genet & Pathol, Uppsala, Sweden
[2] Karolinska Inst, Dept Oncol Pathol, Stockholm, Sweden
[3] Vall dHebron Inst Oncol, Barcelona, Spain
[4] Uppsala Univ, Dept Womens & Childrens Hlth, Uppsala, Sweden
[5] Karolinska Inst, Dept Med, Div Clin Epidemiol, Stockholm, Sweden
关键词
Ovarian cancer; Parity; Progesterone receptor; Tissue micro array; HORMONE-RECEPTOR EXPRESSION; RISK-FACTORS; PROGESTERONE; ESTROGEN; EPITHELIUM; APOPTOSIS; OVULATION; SURVIVAL;
D O I
10.1007/s10552-024-01876-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose High-grade serous ovarian cancer (HGSC) is the most common ovarian cancer subtype. Parity is an important risk-reducing factor, but the underlying mechanism behind the protective effect is unclear. Our aim was to study if the expression of hormones and proteins involved in pregnancy were affected by the woman's parity status, and if they may be associated with tumor stage and survival.Methods We evaluated expression of progesterone receptor (PR), progesterone receptor membrane component 1 (PGRMC1), relaxin-2, and transforming growth factor beta 1 (TGF beta 1) in tumor tissue from 92 women with HGSC parous (n = 73) and nulliparous (n = 19). Key findings were then evaluated in an independent expansion cohort of 49 patients. Survival rates by hormone/protein expression were illustrated using the Kaplan-Meier method. The independent prognostic value was tested by Cox regression, using models adjusted for established poor-prognostic factors (age at diagnosis, FIGO stage, type of surgery, and macroscopic residual tumor after surgery).Results HGSC tumors from parous women were PR positive (>= 1% PR expression in tumor cells) more often than tumors from nulliparous women (42% vs. 16%; p-value 0.04), and having more children was associated with developing PR positive tumors [i.e., >= 3 children versus nulliparity, adjusted for age at diagnosis and stage: OR 4.31 (95% CI 1.12-19.69)]. A similar result was seen in the expansion cohort. Parity status had no impact on expression of PGRMC1, relaxin-2 and TGF beta 1. No associations were seen with tumor stage or survival.Conclusion Tumors from parous women with HGSC expressed PR more often than tumors from nulliparous women, indicating that pregnancies might possibly have a long-lasting impact on ovarian cancer development.
引用
收藏
页码:1101 / 1109
页数:9
相关论文
共 50 条
  • [31] Advances in tumor screening, imaging, and avatar technologies for high-grade serous ovarian cancer
    Ohman, Anders W.
    Hasan, Noor
    Dinulescu, Daniela M.
    FRONTIERS IN ONCOLOGY, 2014, 4
  • [32] Tumor vascularity and versican in high-grade, advanced-stage serous ovarian cancer
    Ghosh, S.
    Nagymanyoki, Z.
    Berkowitz, R.
    Mok, S.
    GYNECOLOGIC ONCOLOGY, 2008, 108 (03) : S51 - S51
  • [33] Singling out tumor heterogeneity and chemoresistance in high-grade serous ovarian cancer.
    Erkan, Erdogan Pekcan
    Dai, Jun
    Zhang, Kaiyang
    Kaipio, Katja
    Lamminen, Tarja
    Mansuri, Naziha
    Suominen, Lasse
    Alkodsi, Amjad
    Huhtinen, Kaisa
    Hietanen, Sakari
    Hynninen, Johanna
    Grenman, Seija
    Carpen, Olli
    Hautaniemi, Sampsa
    Vaharautio, Anna
    CLINICAL CANCER RESEARCH, 2020, 26 (13) : 59 - 59
  • [34] The genomic profile of high-grade serous ovarian cancer and its association with platinum resistance
    Montemorano, Lauren
    Lang, Jessica
    Shultz, Zoey
    Farooque, Alma
    Hyun, Meredith
    Chappell, Richard
    Hartenbach, Ellen
    GYNECOLOGIC ONCOLOGY, 2023, 176 : S290 - S291
  • [35] Association of fusion genes with clinical outcomes and survival in high-grade serous ovarian cancer
    Newtson, A. M.
    Reyes, H. D.
    Lyons, Y. A.
    Cardillo, N. D.
    Russo, D.
    Devor, E.
    Goodheart, M. J.
    Gonzalez-Bosquet, J.
    GYNECOLOGIC ONCOLOGY, 2020, 159 : 103 - 104
  • [36] The Tumor Microenvironment of High Grade Serous Ovarian Cancer
    Stack, M. Sharon
    Nephew, Kenneth P.
    Burdette, Joanna E.
    Mitra, Anirban K.
    CANCERS, 2019, 11 (01):
  • [37] Decreased Levels of GSH Are Associated with Platinum Resistance in High-Grade Serous Ovarian Cancer
    Criscuolo, Daniela
    Avolio, Rosario
    Parri, Matteo
    Romano, Simona
    Chiarugi, Paola
    Matassa, Danilo Swann
    Esposito, Franca
    ANTIOXIDANTS, 2022, 11 (08)
  • [38] Microenvironment cell populations are associated with clinical outcomes in high-grade serous ovarian cancer
    Watson, Rachel
    Linder, Katharine
    Gabrilovich, Sofia
    Ulmer, Keely
    Polio, Andrew
    Goodheart, Michael
    Bender, David
    Bosquet, Jesus Gonzalez
    GYNECOLOGIC ONCOLOGY, 2024, 190 : S196 - S196
  • [39] Principles of dormancy evident in high-grade serous ovarian cancer
    Trevor G. Shepherd
    Frederick A. Dick
    Cell Division, 17
  • [40] Properties of the immune microenvironment associated with clonal diversity in high-grade serous ovarian cancer
    Zhang, Allen W.
    McPherson, Andrew
    Roth, Andrew
    Kroeger, David R.
    Milne, Katy
    Wasserman, Wyeth W.
    McAlpine, Jessica N.
    Holt, Robert A.
    Nelson, Brad H.
    Shah, Sohrab P.
    CANCER RESEARCH, 2016, 76